Advertisement
Bob Ingram is Vice Chairman, Pharmaceuticals at GlaxoSmithKline (plc), andpreviously served as Chief Executive Officer, Chief Operating Officer andPresident of Pharmaceutical operations for Glaxo Wellcome. Mr. Ingram isChairman of the Board of Directors of OSI Pharmaceuticals, Inc. and ValeantPharmaceuticals International, and a member of the Board of Directors ofAllergan, Inc., Lowe's Companies, Edwards Lifesciences Corporation, andWachovia Corporation.
Advertisement
"We are delighted to welcome Bob to the Jennerex team. His experience inleading companies which have successfully developed and commercialized majornew medicines adds significant strategic depth to our team," said BrennanMulcahy, Chairman of Jennerex.
"I am excited to work with the Board and CEO of Jennerex to develop andcommercialize a new class of biotherapeutics for the treatment of severalmajor types of cancer," said Bob Ingram.
"We know Bob's extensive pharmaceutical leadership experience will beinvaluable to Jennerex as we leverage our innovative technology platform todevelop and commercialize major new medicines to treat patients with seriousunmet needs in oncology, including liver cancer, melanoma and lung cancer,"said David H. Kirn, M.D., President and Chief Executive Officer.
Mr. Glick was Executive Vice President and Chief Financial Officer ofTheravance, Inc. until 2005. He led the efforts to successfully raise over$350 million of private and public equity and to form an innovative strategicalliance with GlaxoSmithKline. Prior to Theravance, Mr. Glick held theposition of Vice President Finance at Genentech Inc where he was involved instructuring major deals such as in-licensing of Rituxan(R) from Idec (nowBiogen Idec). Marty was also a co-founder and Board member of EyetechPharmaceuticals.
"Marty's experience in working with top management to successfully financeand build emerging biopharmaceutical companies is an important addition to ourteam as we drive our lead product candidate toward late stage clinicaldevelopment and commercialization," said Dr. Kirn.
About Jennerex
Jennerex Biotherapeutics is a clinical stage biotherapeutics companyworking to create, develop and commercialize first-in-class cancer products.Our products are engineered viruses that have been modified to be safe andeffective against various forms of cancer. Jennerex products kill cancer bytargeting, attacking and eradicating cancer cells. Our lead product candidate,JX-594, has demonstrated clear anti-cancer effects in a Phase 1 study inpatients with late-stage liver cancer. Jennerex has initiated a Phase 2aclinical trial in the U.S., for liver cancer and is currently enrolling aPhase 2a clinical trial at several sites in the U.S. for metastatic melanoma.Jennerex is also planning a Phase 1 study with IV administration focusing onlung cancer and melanoma.
For more information about Jennerex, please visit http://www.jennerex.com.
SOURCE Jennerex, Inc.
